Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8603)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Mar 14, 2015 (publication date) through Apr 1, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Formica V, Roselli M. Targeted therapy in first line treatment of RAS wild type colorectal cancer. World J Gastroenterol 2015; 21(10): 2871-2874 [PMID: 25780283 DOI: 10.3748/wjg.v21.i10.2871] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i10/2871.htm |
| Number | Citing Articles |
| 1 |
Kristen K. Ciombor, Tanios Bekaii-Saab. A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. The Oncologist 2018; 23(1): 25 doi: 10.1634/theoncologist.2017-0203
|
| 2 |
Johnie Rose, Laura Homa, Chung Yin Kong, Gregory S. Cooper, Michael W. Kattan, Bridget O. Ermlich, Jeffrey P. Meyers, John N. Primrose, Sian A. Pugh, Bethany Shinkins, Uriel Kim, Neal J. Meropol. Development and validation of a model to predict outcomes of colon cancer surveillance. Cancer Causes & Control 2019; 30(7): 767 doi: 10.1007/s10552-019-01187-x
|
| 3 |
Cristina Morelli, Vincenzo Formica, Silvia Riondino, Antonio Russo, Patrizia Ferroni, Fiorella Guadagni, Mario Roselli. Irinotecan or Oxaliplatin: Which is the First Move for the Mate?. Current Medicinal Chemistry 2021; 28(16): 3158 doi: 10.2174/0929867327666201016124950
|
| 4 |
Aïssata Aimée Goïta, Dominique Guenot. Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7. Cancers 2022; 14(7): 1810 doi: 10.3390/cancers14071810
|
| 5 |
Jiemin Zhao, Liangrong Shi, Mei Ji, Jun Wu, Changping Wu. The combination of systemic chemotherapy and local treatment may improve the survival of patients with unresectable metastatic colorectal cancer. Molecular and Clinical Oncology 2017; 6(6): 856 doi: 10.3892/mco.2017.1247
|
| 6 |
Razvan Constantin Vonica, Claudiu Morgovan, Anca Butuca, Manuela Pumnea, Remus Calin Cipaian, Adina Frum, Carmen Maximiliana Dobrea, Andreea Loredana Vonica-Tincu, Aliteia-Maria Pacnejer, Florina Batar, Vlad Vornicu, Steliana Ghibu, Felicia Gabriela Gligor. Real-World Evidence of Bevacizumab and Panitumumab Drug Resistance and Drug Ineffectiveness from EudraVigilance Database. Cancers 2025; 17(4): 663 doi: 10.3390/cancers17040663
|
| 7 |
Long Bai, Feng Wang, Zhe-zhen Li, Chao Ren, Dong-sheng Zhang, Qi Zhao, Yun-xin Lu, De-shen Wang, Huai-qiang Ju, Miao-zhen Qiu, Zhi-qiang Wang, Feng-hua Wang, Rui-hua Xu. Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer. Medicine 2016; 95(51): e4531 doi: 10.1097/MD.0000000000004531
|
| 8 |
Ira Ekmekciu, Doreen Maria Zucha, Jens Christmann, Sarah Wisser, Vera Heuer, Buelent Sargin, Stephan Hollerbach, Christof Lamberti, Lothar Müller, Celine Lugnier, Berlinda Verdoodt, Robin Denz, Tobias Terzer, Inke Feder, Anke Reinacher-Schick, Andrea Tannapfel, Iris Tischoff. Exploring the molecular profile of localized colon cancer: insights from the AIO Colopredict Plus registry. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1434791
|
| 9 |
Elie Kassouf, Samer Tabchi, Mustapha Tehfe. Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis. BioDrugs 2016; 30(2): 95 doi: 10.1007/s40259-016-0166-5
|
| 10 |
Wen Tang, Lu Wang, Yan Liu, Dong Xiao. RasGRP Exacerbates Lipopolysaccharide-Induced Acute Kidney Injury Through Regulation of ERK Activation. Open Forum Infectious Diseases 2022; 9(3) doi: 10.1093/ofid/ofac041
|
| 11 |
Haixing Wang, Dongxian Jiang, Qi Song, Chen Xu, Yuan Shi, Xiaojing Li, Jie Huang, Yifan Xu, Akesu Sujie, Haiying Zeng, Yunshi Zhong, Lijie Tan, Yingyong Hou. Prognostic impact and potential interaction of EGFR and c-Met in the progression of esophageal squamous cell carcinoma. Tumor Biology 2016; 37(7): 9771 doi: 10.1007/s13277-015-4692-4
|
| 12 |
Tony Ibrahim, Claude Saer-Ghorra, Vivane Trak-Smayra, Samah Nadiri, Charbel Yazbeck, Maria Baz, Joseph G. Kattan. Molecular characteristics of colorectal cancer in a Middle Eastern population in a single institution. Annals of Saudi Medicine 2018; 38(4): 251 doi: 10.5144/0256-4947.2018.251
|
| 13 |
Vincenzo Formica, Francesco Sera, Chiara Cremolini, Silvia Riondino, Cristina Morelli, Hendrik-Tobias Arkenau, Mario Roselli.
KRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis. JNCI: Journal of the National Cancer Institute 2022; 114(4): 517 doi: 10.1093/jnci/djab190
|
| 14 |
Mercedes Salgado Fernández, Maria Teresa Pérez Hoyos, Isabela Díaz de Corcuera, Alba Vidal Arbués, Marta García de la Torre. Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program. Expert Opinion on Drug Safety 2015; 14(8): 1171 doi: 10.1517/14740338.2015.1057495
|
| 15 |
Razvan Constantin Vonica, Anca Butuca, Claudiu Morgovan, Manuela Pumnea, Remus Calin Cipaian, Adina Frum, Carmen Maximiliana Dobrea, Andreea Loredana Vonica-Tincu, Aliteia-Maria Pacnejer, Steliana Ghibu, Florina Batar, Felicia Gabriela Gligor. Bevacizumab—Insights from EudraVigilance Database on the Assessments of the Safety Profile of Monoclonal Antibodies Used as Targeted Cancer Treatment. Pharmaceuticals 2025; 18(4): 501 doi: 10.3390/ph18040501
|